Demographic study of leukaemia presenting within the first 3 months of life in the Northern Health Region of England

Journal of Clinical Pathology

Volumn 57, Issue 2, 2004, Pages 186-188

  Bajwa, R P S ^a   Skinner, R ^a   Windebank, K P ^a   Reid, M M ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE MARROW CELL; CANCER INCIDENCE; CANCER REGRESSION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DEMOGRAPHY; DOWN SYNDROME; HUMAN; INFANT; LEUKEMIA; MAJOR CLINICAL STUDY; MYELOPROLIFERATIVE DISORDER; POPULATION RESEARCH; PRIORITY JOURNAL; TREATMENT OUTCOME; TRISOMY 21; UNITED KINGDOM;

ACUTE DISEASE; DOWN SYNDROME; ENGLAND; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LEUKEMIA; MALE; MYELOPROLIFERATIVE DISORDERS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 0842265691     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2003.12039     Document Type: Article

References (5)

1. Lange B. The management of neoplastic disorders of haemopoiesis in children with Down's syndrome. Br J Haematol 2000;110:512-24.
2. Bajwa R, Skinner R, Windebank KP, et al. Chemotherapy and marrow transplantation for congenital leukaemia. Arch Dis Child Fetal Neonatal Ed 2001;84:F47-8.
3. Bresters D, Reus ACW, Veerman AJP, et al. Congenital leukaemia: the Dutch experience and review of the literature. Br J Haematol 2002;117:513-24.
4. Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA-1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood 2003;102:981-6.
5. Abe K, Kajii T, Niikawa N. Disomic homozygosity in 21 trisomic cells: a mechanism for transient myeloproliferative syndrome. Hum Genet 1989;82:313-6.